AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
287.47B
Market cap287.47B
Price-Earnings ratio
30.46
Price-Earnings ratio30.46
Dividend yield
1.66%
Dividend yield1.66%
Average volume
5.41M
Average volume5.41M
High today
$93.07
High today$93.07
Low today
$91.70
Low today$91.70
Open price
$92.23
Open price$92.23
Volume
1.18M
Volume1.18M
52 Week high
$94.02
52 Week high$94.02
52 Week low
$61.24
52 Week low$61.24

AZN News

Nasdaq 3d
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for...

AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
Nasdaq 3d
Validea Detailed Fundamental Analysis - AZN

Below is Validea's guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow, AZN rates highest using our P/B Growth Investor...

Validea Detailed Fundamental Analysis - AZN
Benzinga 3d
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial

On Monday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
9.4%
Sell
9.4%

More AZN News

TipRanks 3d
AstraZeneca Targets Chemo-Ineligible Lung Cancer Patients With New Osimertinib Trial

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...

TipRanks 3d
AstraZeneca Moves CAR-T Into Autoimmune Diseases, Adding Long-Term Upside to AZN’s Pipeline

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season AstraZeneca Explores CAR-T for Autoimmune Di...

TipRanks 3d
AstraZeneca says to end U.S. commercial sales of Andexxa

The FDA said in a statement: “Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in...

Benzinga 3d
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market

The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ:AZN) to s...

TipRanks 4d
AstraZeneca Discloses Routine Share Sale by Non-Executive Director

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 4d
Mixed Bag for AZN Stock: AstraZeneca’s Enhertu Wins FDA Breakthrough, Imfinzi Misses Trial Goal

AstraZeneca’s (AZN) breast cancer drug Enhertu has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). The FDA gave th...

TipRanks 4d
AstraZeneca, Daiichi Sankyo dose firs patient in DESTINY-Endometrial02 trial

The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating Enhertu with or without radiotherapy compared to standard of care chemoth...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.